Skip to main content
Erschienen in: Obesity Surgery 6/2012

01.06.2012 | Clinical Research

500 Intragastric Balloons: What Happens 5 Years Thereafter?

verfasst von: Katerina Kotzampassi, Vasilis Grosomanidis, Pyrros Papakostas, Sofia Penna, Efthymios Eleftheriadis

Erschienen in: Obesity Surgery | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The BioEnterics Intragastric Balloon (BIB) has been considered an effective, less invasive method for weight loss, as it provides a permanent sensation of satiety. However, various non-randomized studies suggest BIB is a temporary anti-obesity treatment, which induces only a short-term weight loss. The purpose of this study was to present data of 500 obese who, after BIB-induced weight reduction, were followed up for up to 5 years.

Methods

The BioEnterics BIB was used, and remained for 6 months. At 6, 12, and 24 months post-removal (and yearly thereafter), all subjects were contacted for follow-up.

Results

From 500 patients enrolled, 26 were excluded (treatment protocol interruption); 474 thus remained, having initial body weight of 126.16 ± 28.32 kg, BMI of 43.73 ± 8.39 kg/m2, and excess weight (EW) of 61.35 ± 25.41. At time of removal, 79 (17%) were excluded as having percent excessive weight loss (EWL) of <20%; the remaining 395 had weight loss of 23.91 ± 9.08 kg (18.73%), BMI reduction of 8.34 ± 3.14 kg/m2 (18.82%), and percent EWL of 42.34 ± 19.07. At 6 and 12 months, 387 (98%) and 352 (89%) presented with weight loss of 24.14 ± 8.93 and 16.31 ± 7.41 kg, BMI reduction of 8.41 ± 3.10 and 5.67 ± 2.55 kg/m2, and percent EWL of 42.73 ± 18.87 and 27.71 ± 13.40, respectively. At 12 and 24 months, 187 (53%) and 96 (27%) of 352 continued to have percent EWL of >20. Finally, 195 of 474 who completed the 60-month follow-up presented weight loss of 7.26 ± 5.41 kg, BMI reduction of 2.53 ± 1.85 kg/m2, and percent EWL of 12.97 ± 8.54. At this time, 46 (23%) retained the percent EWL at >20. In general, those who lost 80% of the total weight lost during the first 3 months of treatment succeeded in maintaining a percent EWL of >20 long term after BIB removal: more precisely, this cutoff point was achieved in 83% at the time of removal and in 53%, 27%, and 23% at 12-, 24-, and 60-month follow-up.

Conclusion

BIB seems to be effective for significant weight loss and maintenance for a long period thereafter, under the absolute prerequisite of patient compliance and behavior change from the very early stages of treatment.
Literatur
1.
Zurück zum Zitat WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: WHO; 1998 WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: WHO; 1998
2.
Zurück zum Zitat Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. J Am Med Assoc. 1999;1999(282):1530–8.CrossRef Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. J Am Med Assoc. 1999;1999(282):1530–8.CrossRef
4.
Zurück zum Zitat National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obes Res 1998; 6: 51S–209S. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obes Res 1998; 6: 51S–209S.
5.
Zurück zum Zitat Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res. 2004;12:1197–211.PubMedCrossRef Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res. 2004;12:1197–211.PubMedCrossRef
6.
Zurück zum Zitat Waseem T, Mogensen KM, Lautz DB, et al. Pathophysiology of obesity: why surgery remains the most effective treatment. Obes Surg. 2007;17:1389–98.PubMedCrossRef Waseem T, Mogensen KM, Lautz DB, et al. Pathophysiology of obesity: why surgery remains the most effective treatment. Obes Surg. 2007;17:1389–98.PubMedCrossRef
7.
Zurück zum Zitat Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.PubMedCrossRef Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.PubMedCrossRef
8.
Zurück zum Zitat Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293–316.PubMedCrossRef Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293–316.PubMedCrossRef
9.
Zurück zum Zitat Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes. 2005;29:1168–74.CrossRef Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes. 2005;29:1168–74.CrossRef
10.
Zurück zum Zitat Rossi A, Bersani G, Ricci G, et al. Intragastric balloon insertion increases the frequency of erosive esophagitis in obese patients. Obes Surg. 2007;17:1346–9.PubMedCrossRef Rossi A, Bersani G, Ricci G, et al. Intragastric balloon insertion increases the frequency of erosive esophagitis in obese patients. Obes Surg. 2007;17:1346–9.PubMedCrossRef
11.
Zurück zum Zitat Kotzampassi K, Eleftheriadis E. Intragastric balloon as an alterantive procedure for morbid obesity. Ann Gastroenterol. 2006;19:285–8. Kotzampassi K, Eleftheriadis E. Intragastric balloon as an alterantive procedure for morbid obesity. Ann Gastroenterol. 2006;19:285–8.
12.
Zurück zum Zitat Doldi SB, Micheletto G, Di Prisco F, et al. Intragastric balloon in obese patients. Obes Surg. 2000;10:578–81.PubMedCrossRef Doldi SB, Micheletto G, Di Prisco F, et al. Intragastric balloon in obese patients. Obes Surg. 2000;10:578–81.PubMedCrossRef
13.
Zurück zum Zitat Kotzampassi K, Shrewsbury AD. Intragastric balloon: ethics, medical need and cosmetics. Dig Dis. 2008;26:45–8.PubMedCrossRef Kotzampassi K, Shrewsbury AD. Intragastric balloon: ethics, medical need and cosmetics. Dig Dis. 2008;26:45–8.PubMedCrossRef
14.
Zurück zum Zitat Melissas J. IFSO guidelines for safety, quality, and excellence in bariatric surgery. Obes Surg. 2008;18:497–500.PubMedCrossRef Melissas J. IFSO guidelines for safety, quality, and excellence in bariatric surgery. Obes Surg. 2008;18:497–500.PubMedCrossRef
15.
Zurück zum Zitat Wahlen CH, Bastens B, Herve J, et al. The BioEnterics Intragastric Balloon (BIB): how to use it. Obes Surg. 2001;11:524–7.PubMedCrossRef Wahlen CH, Bastens B, Herve J, et al. The BioEnterics Intragastric Balloon (BIB): how to use it. Obes Surg. 2001;11:524–7.PubMedCrossRef
16.
Zurück zum Zitat Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19–21, 1987. Gastrointest Endosc. 1987;33:323–7.PubMedCrossRef Schapiro M, Benjamin S, Blackburn G, et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19–21, 1987. Gastrointest Endosc. 1987;33:323–7.PubMedCrossRef
17.
Zurück zum Zitat Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19:1084–8.PubMedCrossRef Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19:1084–8.PubMedCrossRef
18.
Zurück zum Zitat Imaz I, Martínez-Cervell C, García-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6.PubMedCrossRef Imaz I, Martínez-Cervell C, García-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6.PubMedCrossRef
19.
Zurück zum Zitat Mui WL, Ng EK, Tsung BY, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20:1128–32.PubMedCrossRef Mui WL, Ng EK, Tsung BY, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20:1128–32.PubMedCrossRef
20.
Zurück zum Zitat Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.PubMedCrossRef Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.PubMedCrossRef
21.
Zurück zum Zitat Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.PubMedCrossRef Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.PubMedCrossRef
22.
Zurück zum Zitat Mion F, Gincul R, Roman S, et al. Tolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter study. Obes Surg. 2007;17:764–9.PubMedCrossRef Mion F, Gincul R, Roman S, et al. Tolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter study. Obes Surg. 2007;17:764–9.PubMedCrossRef
23.
Zurück zum Zitat Deitel M. How much weight loss is sufficient to overcome major co-morbidities? Obes Surg. 2001;11:659.PubMedCrossRef Deitel M. How much weight loss is sufficient to overcome major co-morbidities? Obes Surg. 2001;11:659.PubMedCrossRef
24.
Zurück zum Zitat Spyropoulos C, Katsakoulis E, Mead N, et al. Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy. Surg Obes Relat Dis. 2007;3:78–83.PubMedCrossRef Spyropoulos C, Katsakoulis E, Mead N, et al. Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy. Surg Obes Relat Dis. 2007;3:78–83.PubMedCrossRef
25.
Zurück zum Zitat Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26:40–4.PubMedCrossRef Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26:40–4.PubMedCrossRef
26.
Zurück zum Zitat Dumonceau JM, François E, Hittelet A, et al. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes Surg. 2010;20:692–7.PubMedCrossRef Dumonceau JM, François E, Hittelet A, et al. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes Surg. 2010;20:692–7.PubMedCrossRef
27.
Zurück zum Zitat Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics® Intragastric Balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21:5–9.PubMedCrossRef Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics® Intragastric Balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21:5–9.PubMedCrossRef
28.
Zurück zum Zitat Dastis NS, François E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575–80.PubMedCrossRef Dastis NS, François E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575–80.PubMedCrossRef
29.
Zurück zum Zitat Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18:1611–7.PubMedCrossRef Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18:1611–7.PubMedCrossRef
30.
Zurück zum Zitat Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14:991–8.PubMedCrossRef Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14:991–8.PubMedCrossRef
31.
Zurück zum Zitat Al-Momen A, El-Mogy I. Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15:101–5.PubMedCrossRef Al-Momen A, El-Mogy I. Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15:101–5.PubMedCrossRef
32.
Zurück zum Zitat Totté E, Hendrickx L, Pauwels M, et al. Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg. 2001;11:519–23.PubMedCrossRef Totté E, Hendrickx L, Pauwels M, et al. Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg. 2001;11:519–23.PubMedCrossRef
33.
Zurück zum Zitat Fernandes M, Atallah AN, Soares BG, Humberto S, Guimarães S, Matos D, Monteiro L, Richter B. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;(1):CD004931 Fernandes M, Atallah AN, Soares BG, Humberto S, Guimarães S, Matos D, Monteiro L, Richter B. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;(1):CD004931
Metadaten
Titel
500 Intragastric Balloons: What Happens 5 Years Thereafter?
verfasst von
Katerina Kotzampassi
Vasilis Grosomanidis
Pyrros Papakostas
Sofia Penna
Efthymios Eleftheriadis
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 6/2012
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-012-0607-2

Weitere Artikel der Ausgabe 6/2012

Obesity Surgery 6/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.